Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through… Read more
Evogene (EVGN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.189x
Based on the latest financial reports, Evogene (EVGN) has a cash flow conversion efficiency ratio of -0.189x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.79 Million) by net assets ($20.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Evogene - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Evogene's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Evogene Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evogene ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ARGO BLOCKCHAIN LS -001
F:0XP
|
N/A |
|
TOP Ships Inc.
NASDAQ:TOPS
|
0.110x |
|
P9J
F:P9J
|
-0.696x |
|
Greenvale Energy Ltd
AU:GRV
|
0.090x |
|
Personel Alih Daya
JK:PADA
|
-0.041x |
|
TalkPool AG
ST:TALK
|
0.305x |
|
Ashot Ashkelon Industries Ltd
TA:ASHO
|
0.613x |
|
Freelancer Limited
PINK:FLNCF
|
0.035x |
Annual Cash Flow Conversion Efficiency for Evogene (2011–2024)
The table below shows the annual cash flow conversion efficiency of Evogene from 2011 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $14.84 Million | $-19.70 Million | -1.328x | -76.50% |
| 2023-12-31 | $28.68 Million | $-21.58 Million | -0.752x | -10.52% |
| 2022-12-31 | $34.79 Million | $-23.68 Million | -0.681x | -73.77% |
| 2021-12-31 | $63.42 Million | $-24.84 Million | -0.392x | -14.17% |
| 2020-12-31 | $56.88 Million | $-19.51 Million | -0.343x | -18.97% |
| 2019-12-31 | $60.22 Million | $-17.36 Million | -0.288x | +4.32% |
| 2018-12-31 | $50.31 Million | $-15.16 Million | -0.301x | -31.26% |
| 2017-12-31 | $69.38 Million | $-15.93 Million | -0.230x | -71.40% |
| 2016-12-31 | $87.29 Million | $-11.69 Million | -0.134x | -12.02% |
| 2015-12-31 | $103.75 Million | $-12.41 Million | -0.120x | -56.06% |
| 2014-12-31 | $116.08 Million | $-8.89 Million | -0.077x | -81.38% |
| 2013-12-31 | $124.75 Million | $-5.27 Million | -0.042x | -7.98% |
| 2012-12-31 | $48.26 Million | $-1.89 Million | -0.039x | -188.20% |
| 2011-12-31 | $48.09 Million | $2.13 Million | 0.044x | -- |